Cat. No.: HY-10332

(Z)-Semaxanib

(Synonyms: (Z)-SU5416)

4 Cited Publications

고객리뷰

Based on 4 publication(s) in Google Scholar

(Z)-Semaxanib (compound (z)-1) is a potent tyrosine kinase inhibitor. (Z)-Semaxanib shows cytotoxicity for TAMH and HepG2 cells with IC₅₀s of 6.28 µM and 8.17 µM, respectively.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.72%
CAS No.: 194413-58-6
화학식: C₁₅H₁₄N₂O
분자량:238.29

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

(Z)-Semaxanib Chemical Structure

CAS No.: 194413-58-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
Chemical Information
Publications (4)
용액&용해도
- In Vitro
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

(Z)-Semaxanib (compound (z)-1) is a potent tyrosine kinase inhibitor. (Z)-Semaxanib shows cytotoxicity for TAMH and HepG2 cells with IC₅₀s of 6.28 µM and 8.17 µM, respectively^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	GI₅₀	37 μM Compound: Semaxanib	Growth inhibition of human A431 cells after 72 hrs by trypan blue assay Growth inhibition of human A431 cells after 72 hrs by trypan blue assay	[PMID: 29547832]
A-431	GI₅₀	37 μM Compound: Semaxanib	Growth inhibition of human A431 cells incubated for 72 hrs by trypan blue assay Growth inhibition of human A431 cells incubated for 72 hrs by trypan blue assay	[PMID: 30996779]
A-431	IC₅₀	0.085 μM Compound: 9, SU-5416	Antiangiogenic activity against human A431 cells Antiangiogenic activity against human A431 cells	[PMID: 20403693]
A-431	IC₅₀	12.9 μM Compound: SU-5416	Inhibition of VEGFR2 expressed in human A431 cells Inhibition of VEGFR2 expressed in human A431 cells	[PMID: 20558072]
A-431	IC₅₀	19.2 μM Compound: 7, SU-5416	Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay Cytotoxicity against human A431 cells overexpressing EGFR incubated for 12 hrs measured after 36 hrs by CYQUANT assay	[PMID: 22370340]
A-431	IC₅₀	19.2 μM Compound: 9, SU-5416	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 20403693]
A-431	IC₅₀	19.2 μM Compound: SU-5416, semaxanib	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 18467105]
B16-F10	IC₅₀	0.0036 μM Compound: Semaxanib	Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay	[PMID: 23777898]
BaF3	IC₅₀	>50 μM Compound: SU-5416	Growth inhibition of mouse BA/F3 cells assessed as incorporation of [3H]thymidine incorporation after 72 hrs by liquid scintillation counting Growth inhibition of mouse BA/F3 cells assessed as incorporation of [3H]thymidine incorporation after 72 hrs by liquid scintillation counting	[PMID: 20117004]
HeLa	GI₅₀	38 μM Compound: Semaxanib	Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay Growth inhibition of human HeLa cells after 72 hrs by trypan blue assay	[PMID: 29547832]
HeLa	GI₅₀	38 μM Compound: Semaxanib	Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay	[PMID: 30996779]
HeLa	IC₅₀	20 μM Compound: SU5416	Antiproliferative activity against human HeLa cells after 4 days by coulter counter method Antiproliferative activity against human HeLa cells after 4 days by coulter counter method	[PMID: 23124213]
HMEC-1	IC₅₀	15 μM Compound: SU5416	Antiproliferative activity against human HMEC1 cells after 7 days by coulter counter method Antiproliferative activity against human HMEC1 cells after 7 days by coulter counter method	[PMID: 23124213]
HUVEC	GI₅₀	13.6 μM Compound: Semaxanib	Growth inhibition of HUVEC incubated for 72 hrs by trypan blue assay Growth inhibition of HUVEC incubated for 72 hrs by trypan blue assay	[PMID: 30996779]
HUVEC	GI₅₀	13.6 μM Compound: SU5414, Semaxanib	Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability after 72 hrs by trypan blue assay Antiproliferative activity against human HUVEC cells assessed as reduction in cell viability after 72 hrs by trypan blue assay	[PMID: 26318056]
HUVEC	IC₅₀	>50 μM Compound: 1	Evaluated for the inhibition of cell proliferation induced by EGF in HUVEC or NIH3T3 cells Evaluated for the inhibition of cell proliferation induced by EGF in HUVEC or NIH3T3 cells	[PMID: 10893303]
HUVEC	IC₅₀	0.04 μM Compound: 1	Evaluated for the inhibition of cell proliferation induced by VEGF in HUVEC or NIH3T3 cells Evaluated for the inhibition of cell proliferation induced by VEGF in HUVEC or NIH3T3 cells	[PMID: 10893303]
HUVEC	IC₅₀	4.54 μM Compound: 1	Evaluated for the inhibition of cell proliferation induced by PDGF in HUVEC or NIH3T3 cells Evaluated for the inhibition of cell proliferation induced by PDGF in HUVEC or NIH3T3 cells	[PMID: 10893303]
HUVEC	IC₅₀	50 μM Compound: 1	Evaluated for the inhibition of cell proliferation induced by FGF in HUVEC or NIH3T3 cells Evaluated for the inhibition of cell proliferation induced by FGF in HUVEC or NIH3T3 cells	[PMID: 10893303]
MCF7	IC₅₀	>50 μM Compound: SU-5416	Antiproliferative activity against estrogen-dependent breast cancer MCF7 cell line by MTS assay Antiproliferative activity against estrogen-dependent breast cancer MCF7 cell line by MTS assay	[PMID: 16213720]
MCF7	IC₅₀	0.0031 μM Compound: Semaxanib	Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay	[PMID: 23777898]
MCF7	IC₅₀	1.9 μM Compound: SU5416	Antiproliferative activity against human MCF7 cells after 4 days by coulter counter method Antiproliferative activity against human MCF7 cells after 4 days by coulter counter method	[PMID: 23124213]
MDA-MB-231	IC₅₀	>50 μM Compound: SU-5416	Antiproliferative activity against estrogen-independent breast cancer MDA-MB-231 cell line by MTS assay Antiproliferative activity against estrogen-independent breast cancer MDA-MB-231 cell line by MTS assay	[PMID: 16213720]
MSTO-211H	GI₅₀	27 μM Compound: Semaxanib	Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells after 72 hrs by trypan blue assay	[PMID: 29547832]
MSTO-211H	GI₅₀	27 μM Compound: Semaxanib	Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay	[PMID: 30996779]
PBMC	IC₅₀	0.005 μM Compound: 1 (SU-5416)	In vitro inhibitory concentration on the production of pro-inflammatory cytokine IL-2 in PBMC (Peripheral blood mononuclear cells) determined by IL-2 PBMC assay In vitro inhibitory concentration on the production of pro-inflammatory cytokine IL-2 in PBMC (Peripheral blood mononuclear cells) determined by IL-2 PBMC assay	[PMID: 16107139]
PC-3	IC₅₀	>50 μM Compound: SU-5416	Antiproliferative activity against androgen-independent prostate cancer PC3 cell line by MTS assay Antiproliferative activity against androgen-independent prostate cancer PC3 cell line by MTS assay	[PMID: 16213720]
SF-539	IC₅₀	2.4 μM Compound: SU-5416	Inhibition of PDGFRbeta in human SF539 cells by phosphotyrosine ELISA Inhibition of PDGFRbeta in human SF539 cells by phosphotyrosine ELISA	[PMID: 19748785]
Sf9	IC₅₀	0.17 μM Compound: SU-5416	Inhibition of human recombinant His-tagged RET expressed in Sf9 insect cells Inhibition of human recombinant His-tagged RET expressed in Sf9 insect cells	[PMID: 20117004]
Sf9	IC₅₀	20.7 μM Compound: 23	Inhibition of human GST-fused ZAP-70 expressed in Sf9 cells Inhibition of human GST-fused ZAP-70 expressed in Sf9 cells	[PMID: 19674816]
Sf9	IC₅₀	3 μM Compound: SU5416	Inhibition of GST-Flt1 kinase domain (unknown origin) expressed in baculovirus infected Sf9 cells after 20 mins by scintillation counting Inhibition of GST-Flt1 kinase domain (unknown origin) expressed in baculovirus infected Sf9 cells after 20 mins by scintillation counting	[PMID: 23414235]
U-251	IC₅₀	12 μM Compound: 18, SU-5416	Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA	[PMID: 22204741]
U-251	IC₅₀	12 μM Compound: 20	Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA	[PMID: 23434139]
U-251	IC₅₀	12 μM Compound: 27	Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
U-251	IC₅₀	12 μM Compound: 46, SU-5416	Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA	[PMID: 20403700]
U-251	IC₅₀	12.9 nM Compound: Semaxanib	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay	[PMID: 24890652]
U-251	IC₅₀	12.9 nM Compound: Semaxanib	Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
U-251	IC₅₀	12.9 nM Compound: semaxinib	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA	[PMID: 24900865]
U-251	IC₅₀	12.9 μM Compound: SU-5416	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA	[PMID: 20092323]
U-251	IC₅₀	12.9 μM Compound: SU-5416	Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
U-251	IC₅₀	2.43 μM Compound: 7, SU-5416	Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA	[PMID: 22370340]

Chemical Information

CAS No. 194413-58-6
Appearance Solid
분자량 238.29
화학식 C₁₅H₁₄N₂O
Color Yellow to orange
SMILES

O=C(NC1=C/2C=CC=C1)C2=C/C3=C(C)C=C(C)N3
Synonyms

(Z)-SU5416
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Br J Pharmacol

VEGFR-2 blocker induces pulmonary vascular disease in rats with CRISPR-edited human non-deficient G6PD polymorphism: role of 3D genomic modifications and DNA methylation. [Abstract]

2026 May 5. PMID: 42083756
Int J Mol Sci

Curcuminoids Inhibit Angiogenic Behaviors of Human Umbilical Vein Endothelial Cells via Endoglin/Smad1 Signaling. [Abstract]

2022 Mar 31;23(7):3889. PMID: 35409247
Authorea

June 28, 2022.

용액&용해도

In Vitro:

DMSO : 50 mg/mL (209.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1966 mL

20.9828 mL

41.9657 mL

5 mM

0.8393 mL

4.1966 mL

8.3931 mL

10 mM

0.4197 mL

2.0983 mL

4.1966 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ngai MH, So CL, Sullivan MB, Ho HK, Chai CL. Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones. ChemMedChem. 2016 Jan 5;11(1):72-80. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1966 mL	20.9828 mL	41.9657 mL	104.9142 mL
	5 mM	0.8393 mL	4.1966 mL	8.3931 mL	20.9828 mL
	10 mM	0.4197 mL	2.0983 mL	4.1966 mL	10.4914 mL
	15 mM	0.2798 mL	1.3989 mL	2.7977 mL	6.9943 mL
	20 mM	0.2098 mL	1.0491 mL	2.0983 mL	5.2457 mL
	25 mM	0.1679 mL	0.8393 mL	1.6786 mL	4.1966 mL
	30 mM	0.1399 mL	0.6994 mL	1.3989 mL	3.4971 mL
	40 mM	0.1049 mL	0.5246 mL	1.0491 mL	2.6229 mL
	50 mM	0.0839 mL	0.4197 mL	0.8393 mL	2.0983 mL
	60 mM	0.0699 mL	0.3497 mL	0.6994 mL	1.7486 mL
	80 mM	0.0525 mL	0.2623 mL	0.5246 mL	1.3114 mL
	100 mM	0.0420 mL	0.2098 mL	0.4197 mL	1.0491 mL

Keywords

(Z)-Semaxanib

4 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

(Z)-Semaxanib

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

FDA-Approved Anticancer Drug Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

FDA Kinase Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) (Z)-Semaxanib

Biological Activity

Chemical Information

Publications (4)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

(Z)-Semaxanib

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

FDA-Approved Anticancer Drug Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cytokine Inhibitors Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

FDA Kinase Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) (Z)-Semaxanib

Biological Activity

Chemical Information

Publications (4)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

(Z)-Semaxanib Related Classifications

HY-10332 Related Classifications